News About: Pharm. Industry
Mixed reactions over stem cell
Recent advances in stem-cell research have raised new hopes and uneasiness. On the hope front comes the discovery that stem cells can be derived from reprogrammed adult skin cells, making it appear less important to u...
Janssen’s new prescription pain treatment to be available in March
Janssen Korea says Jurnista prolonged-release tablets (hydromorphone HCl), a new prescription treatment for severe pain, will be available here in March, under health insurance coverage.
Jurnista was developed by A...
Bausch & Lomb names sales head in Korea
Bausch & Lomb South Asia Inc has hired Kim Yeo-jin, former executive of AstraZeneca Korea, to lead its Korea business operations
“Kim is expected to play a central role in optimizing our product portfolio with ins...
Civic group calls for re-nomination of drug screening committee
A civic group People’s Solidarity for Participatory Democracy and other civic groups denounced on February 20 the Health Insurance Review and Assessment’s recent nomination of its newly launched drug screening committ...
CJ to join stem cell business
CJ CheilJedang, a local conglomerate in foods, plans to join the cord blood derived stem cell projects, co-promoted by the Seoul Special City and Seoul National University (SNU), led by professor Kang Kyung-sun.
Th...
Dongwha recruits female executive
Dongwha says it has recently appointed Professor Choo Young-shil, Eulgi medical college, as new executive managing director.
Choo becomes the first female executive in the company since its 112-year foundation.
...
Samil to increase Zyrtec price by 10%
Samil Pharm plans to increase its supply price of Zyrtec tablets and liquids (cetirizine hydrochloride) from this April by about 10 percent except for Zyrtec Plus, saying its price hike is inevitable due to the Korean...
KPMA head likely to stay
Ahnkook chairman Ur Choon-sun is likely to be re-nominated as new chairman of the Korea Pharmaceutical Manufacturers association
In the board of directors' meeting on February 20, Ur was nominated as the new KPMA ...
Drugmakers seek risk-averse management amid economic slump
The majority of pharmaceutical firms here are expected to become more conservative this year in the wake of the ongoing global credit crunch and economic downturn, strengthening risk management and mobilizing the work...
Dongwha seeking to secure cash
Dongwha Pharm said in regulatory filing that it plans to dispose of stakes in its plant and research center at Anyang, Kyunggi Province to Sungji Construction Co., to secure cash.
Through the disposal, the company ...
